

Detection of Sak Gene and Expression of Staphylokinase in Different Clinical Isolates of *Staphylococcus* spp.

Suha Maher Abed , Adnan F. Al-Azzawie

Department of Biology , College of Science , Tikrit University , Tikrit , Iraq

DOI: <http://dx.doi.org/10.25130/tjps.23.2018.007>

ARTICLE INFO.

Article history:

-Received: 30 / 5 / 2017

-Accepted: 5 / 11 / 2017

-Available online: / / 2018

Keywords: Staphylokinase, *Staphylococcus aureus*, *sak* gene, *Staphylococcus* spp., phenotypic assay, PCR

Corresponding Author:

Name: Suha Maher Abed

E-mail:

Suha_maher84@yahoo.com

Tel:

Affiliation:

Abstract

This study had investigated the presence of Staphylokinase (SAK) phenotypically and genetically. A total of 100 *Staphylococcus* spp. samples were isolated from different clinical cases. Morphological, biochemical tests and for further conformation; Vitek2 technique were adopted to isolate and diagnose the staphylococcal samples. Phenotypic assay tests including hydrolysis of casein and plasma agar were performed to check for the production of Staphylokinase from producing *Staphylococcus* spp. Out of 100, only 32 isolates had exhibited (SAK) activity whereby 29 of them represented the species *S. aureus* while 3 belonged to others. All isolates were subjected to Polymerase Chain Reaction (PCR) to determine the possessed *sak* gene. This investigation certainly had shown that not all isolates of *S. aureus* has the *sak* gene, only the lysogenic one has it and that it is not species committed but also other staphylococcus species could have it.

Introduction

The genus *Staphylococcus* considered to be a Gram-positive bacteria that colonize human or animal skin and mucosal membranes. They were basically subdivided into groups depending on novobiocine susceptibility/resistance and coagulase activity, whereby *S. aureus* is novobiocine-resistant and coagulase-positive. Nowadays, due to large differences in pathogenicity, the staphylococci are often categorized into *S. aureus* and CNS, the latter being a combined group of all other species. Also *S. aureus* is an opportunistic pathogen and cause a wide range of diseases. Among staphylococci, it is the most invasive species and an etiological agent of diverse human and animal maladies [1, 2, 3]. It has a unique character of producing an extracellular enzyme which is called Staphylokinase or "spreading factor" that has a role in anti-clotting functioning thereby avoiding the body's fibrinous Reactions (as a wall-off barrier) [4]. This extracellular protein (136 amino acid) aids to disrupt blood clotting throughout altering plasminogen to plasmin. The kinase enzyme also has proteolytic activity which helps to degrade the fibrin clot, a major constituent of thrombus. The blockage of blood vessels can cause myocardial disorders due to blood clot eventually leading to death [5, 6]. Staphylokinase; the single chain protein

with 15.5 kDa is considered as a bolus thrombolytic that aids in chasing or partial digesting of the plasminogen to an inactive pro-enzyme; plasmin with high fibrin specificity thus acting as a clot dissolver [7, 8, 9, 10].

The aim of this study was to isolate *staphylococcus aureus* and screen for Staphylokinase (SAK) from pathogenic staphylococci species phenotypically and genetically using specific PCR.

Materials and Methods

Sample collection and growth conditions

Samples were collected from different clinical cases at Tikrit teaching hospital, outside patients of dermatology and E.N.T clinics and emergency wards. All sample isolates were grown at 37°C for 24 hours in the incubator on mannitol salt agar medium (samples that did not show any growth were excluded and not counted). The bacterial cultures from the mannitol salt agar were taken and the isolates were submitted for biochemical and other tests which included: Gram's staining, Coagulase tube and slide tests, Catalase test culturing on DNAase agar and pigmentation to differentiate the pathogenic *Staphylococcus* spp. following procedures conducted by [11, 12, 13, 14].

Automated identification and characterisation of *Staphylococcus spp.* by VITEK2

Further identification (confirmation) was also carried out by VITEK2 system (BioMérieux VITEK, USA) to characterize the *Staphylococcus spp.* This system accommodate colorimetric reagent cards that are incubated and interpreted automatically. According to the manufacturers' instructions. Micro plates for Gram positive organisms (GP) were used [15].

Phenotypic assay for staphylokinase producing *Staphylococcus aureus* and other species

Screening the enzyme phenotypically was conducted using skimmed milk and heated plasma agar assays and the result was shown as a clearance zone around the wells.



1- Skimmed Milk hydrolytic test

This casein- agar lytic assay was conducted by preparing nutrient agar then adding non- fat milk

regularly to the media followed by the addition of fresh human serum percent as a supplement (2 ml percent). Well diffusion plate technique was used to see the hydrolysis of casein (proteolytic) activity since the produced enzyme utilizes the casein present in the media [16].


2- Human-heated plasma agar test

This test was performed by collecting freshly human blood obtained in tubes with an anti-coagulant agent (EDTA). The tubes of blood were then centrifuged at 10,000 rpm for 10 min. supernatant (plasma) was gathered out and heated in the water bath for 20 min at 56°C. The heated plasma was then cooled to optimum temperature and added to nutrient agar and mixed well by shaking (15ml of nutrient agar medium was prepared, 10 ml of plasma was added) and poured into petri dishes. Well diffusion was also used in this technique [17].

**(1) Casein hydrolysis assay****(2) Heated plasma assay****Figure (1) screening For Enzyme Production****Genomic DNA Extraction**

A simple and rapid method was used for the preparation of staphylococcal genomic DNA following a procedure presented by Hoffman *et al* and Moore *et al* [18, 19] with minor modification. Purity and concentration of DNA samples were estimated by nanodrop, at a wavelength of

A260/A280 nm and to check the quality of the total DNA, agarose gel electrophoresis was determined. Samples were mixed with loading buffer (loading: DNA 2/7 v/v) and loaded into the wells of the gel and visualized by ethidium bromide following procedure of Al- Noami [20].

**Figure (2) Electrophoresis gel for genomic DNA of some *Staphylococcus spp.* isolates by electrophoresis on 1% agarose gel stained with ethidium bromide****Identification of *Sak* Gene from Isolated Sample**

The nucleotide sequences of the full length *sak* gene primers (24 nt forward primer: CGCGGATCCTCAAGTTCATTCGAC and 27 nt reverse primer: CCCAAGCTTTTTCCTTCTATAACAAC) was used in this study (their respective amplified products was 489 bp) [21].

The reaction mixture were prepared according to the instruction of AccuPower PCR PreMix from (BiONEER, Korea), the primer used was at optimum concentration of 10 pmol. Deionized sterile water was used to adjust the volume of this mix was adjusted to

25 µL. DNA amplification was carried out in a Labnet thermocycler for 35 cycles following profile: an initial step 95°C for 5 min, 95°C for 1 min, 54°C for 1 min, 72°C for 1 min, ending with a final extension at 72°C for 5 min. PCR product (7 µl) was observed in a 2% agarose gel in 1x TBE buffer 45 V, 60 Am for 10 min at the first run followed immediately with 120vol, 200Am for 65 min to separate the different amplification products efficiently. The gel was stained via ethidium bromide and photographed using gel documentation system. Molecular characterization of the *sak* gene was

conducted with by running against a 100bp DNA ladder [22].




Figure (3) specific PCR detection of sak gene on 2% agarose gel electrophoresis, lane M referred to 100bp. DNA ladder

Results and Discussion

All isolates included in this research were subjected to check for the production of staphylokinase and they were categorized according to their source of infection after they had been identified and diagnosed at the species level based on their micro and macro characteristics and Vitek technique. To study the capability of *Staphylococcus* spp. strains on

producing staphylokinase two in vitro methods had been undertaken followed by molecular verification.

Table (1) Results for The screening of staphylokinase

	<i>S. aureus</i>	Other species	Total No.
Sak. positive	28	4	32
Sak. negative	52	16	68
Total No.	80	20	100

Table (2) presence of staphylokinase concerning with source of *Staphylococcal* spp. infection

Source	Skin	Ear	Wounds	Burns	Urine	Total No. (%)
Staphylokinase						
Presence	11	8	3	1	9	32
Absence	19	18	10	7	14	68
Total Number	30	26	13	8	23	100

Results illustrated in table 2 above showed that skin source infection had scored high level of staphylokinase (11 out of 32) comparing with others, agreed with Bokarewa and Tarkowski [23] who demonstrated high rate of staphylokinase expression in their clinical samples isolated from skin and other external mucosal origin and relative low levels in isolates invading internal organs. Also the result agreed with what was published by Hameed [24] about staphylokinase production.

The plasmolytic activity and casein hydrolysis were both identified by a halo zone around the growth of colonies matching results between those tests were close favoring the heated plasma agar test observing larger clear zone ≤ 30 mm and the highest ratio of positive results in plasma test was quite a bit more than in casein hydrolysis assay and this almost agreed with Jasim *et al* [25]. The gel electrophoresis of genomic DNA had revealed a good size band knowing that all concentration of DNA samples were uniformed on 50. The quantity obtained with this protocol ranged between 350 ng-500 ng/ μ l, the

variation in amount depended up on the growth of cells. The gene *sak* was detected from the total DNA (genomic) of a lysogenic *S. aureus* and other species (*S. scuri* and *S. xylois*). Expression of *Staphylokinase* from clinical samples to detect its presence using skimmed milk agar and plasma agar hydrolysis assays had occurred followed by the detection of the possessed *sak* gene. The comparative results between Phenotypic and genotypic characteristics of staphylokinase were compatible in terms of the presence and absence and also the intensity (strong positive) and the very sharp band had referred the copy number of this gene. Remarkably, figure 3 illustrate that samples (1-10, 18) showed clear obvious thick band while others were less thought they harbored the gene. Jasim and his partners [26] declared in their work that bacteriophages which invade many bacterial species contribute to control the expression of virulence factors and evolutions of pathogenicity which might explain the current results. On the other hand, taking in consideration all screened isolates, two isolates belonging to the *S.*

sciuri species had recorded the position of staphylokinase and that agreed with the study achieved by Zeman and others [27] who posted that the genome of phage $\phi 575$ harbors genes for staphylokinase and phospholipase in the bacterial host (*S. sciuri*). Staphylokinase, which is a plasminogen activator and a good promising agent for clot dissolving by forming a 1:1 stoichiometric complex with inactive human plasminogen (hPg) circulating in the blood that is followed by cleavage of 10 amino acids from N-terminal by hydrolysis of Lys¹⁰-Lys¹¹ peptide bond and finally forms catalytically active SAK. This catalytically active SAK - plasminogen complex later forms a ternary complex with another molecule of plasminogen and transform this plasminogen to plasmin (hPm) after the cleavage of the Arg⁵⁶¹-Val⁵⁶² peptide bond in hPg for that, this resultant SAK-plasmin complex functions as a plasminogen activator for the conversion formation in the clot [28, 29].

References

1. Malachowa N., DeLeo F. R., Mobile genetic elements of *Staphylococcus aureus*, *J. of Cell. Mol. Life Sci.* 2010, 67: 3057-3071.
2. Braem G., Prevalence of coagulase-negative staphylococci on the teat skin of cows in Flemish dairy herds, Ph.D. thesis, Vrije Universiteit Brussel, Brussels, 2012.
3. David M. Z. and Daum R.S., Community-Associated Methicillin-Resistant *Staphylococcus aureus*: Epidemiology and Clinical Consequences of an Emerging Epidemic, *J. of Clinic. Microbiol. Reviews*, 2010, 23 (3): 616-687.
4. Morello J. A., Granato P. A., Mizer H. E., Laboratory Manual and Workbook in Microbiology Applications to Patient Care, 7th Edition, 2003, The McGraw-Hill.
5. Sirinivasan V. M., Devi C.S., Saha A. *et al.*, Screening For Staphylokinase Producing *Staphylococcus* spp. From Bovine Milk Sample, *J. of Pharmacy and Pharmaceutical Sciences* 2013, 5 (2): 601-604.
6. Collen D., Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction *Circulation*, 1993, 87:1850-1853.
7. Pinel-Marie M., Brielle R., and Felden B., Dual Toxic-Peptide-Coding *Staphylococcus aureus* RNA under Antisense Regulation Targets Host Cells and Bacterial Rivals Unequally, *J. of celrep.*, 2014, 7 : 424-435.
8. Burian M., Wolz C., Goerke C., Regulatory Adaptation of *Staphylococcus aureus* during Nasal Colonization of Humans, *J. PLoS ONE*, 2010, 5 (4): e10040.
9. Devi C.S., Sinha D., Sharma V. AND. Mohanasrinivasan V., Screening For Staphylokinase Producing *Staphylococcus* spp. From Different Environmental Samples, *Asian J Pharm Clin Res*, 2012, 5: (4) 125-128.
10. Ohman E. M., Harrington R. A., Cannon Ch. P. *et al.*, Intravenous Thrombolysis in Acute Myocardial Infarction, Sixth ACCP Consensus Conference on Antithrombotic Therapy, 2001: 253s-277s.
11. Tadesse A., Alem M., Medical Bacteriology, Lecture Notes Degree and Diploma Programs For Environmental Health Students, University of Gondar, Ethiopia, 2006.
12. Forbes B. A., Sahm D. F., Weissfeld A. S., Bailey & Scott's Diagnostic Microbiology, 12th Edition, Mosby, Philadelphia, USA, 2007 p223.
13. Shanmugam S., Selvarajan R., Thangiah S., Drug resistance of *Staphylococcus aureus* in sinusitis patients, *Int. J. of Biosci.* 2011, 1(3):63-71.
14. Elmanama A. A., Diagnostic Medical Microbiology, Medical Technology Department Islamic University-Gaza, 2007, p86.
15. BioMérieux VITEK, Inc., Standard Operating Procedure for VITEK 2 Compact: Use, aintenance and Quality Control Procedures, SOP Number: QC-22-00, 2006.
16. Devi S. C., Kalita D., Vaishnavi.B *et al.*, Production and purification of staphylokinase from *Staphylococcus hominis* MSD1 isolated from Kadi: A traditional Indian fermented food, *International J. of Pharm Tech Research*, 2015, 8, (6): 265-272.
17. Mohanasrinivasan V., Devi C.S., Biswas R *et al.*, Enhanced production of nattokinase from UV mutated *Bacillus* sp., *Bangladesh J Pharmacol* 2013; 8: 110-115.
18. Hoffman L. and Jarvis B.W., DNA Purification from Hard-to-Lyse Bacteria Using Ready-Lyse™ Lysozyme and the MasterPure™ DNA Purification Kit, *EPICENTRE*, 2003,10, cited by www.epicentre.com.
19. Moore E., Arnscheidt A., Kruger A., Strompl C. and Mau M., Simplified protocols for the preparation of genomic DNA from bacterial cultures, *Molecular Microbial Ecology Manual*, 2nd Ed. 2004, 1(01): 3-18.

20. Al- Noaami R. J., Detection the Genotype Estimation of Allele Frequencies for ABO Groups and Rh Factor in Populations of Salah Al-Dine and Kirkuk and Neneva Provinces, Ph.D. thesis, College of Education, Tikrit University, 2014.
21. Pulicherla k.k., Gadupudi G.S., Gadupudi V.P.B., et al., Isolation, Cloning and Expression of Mature Staphylokinase from Lysogenic *Staphylococcus aureus* Collected from a Local Wound Sample in a Salt Inducible *E.coli* Expression Host, *Inter. J. of Advanced Sci. and Technol.* 2011, 30: 35-42.
22. Pulicherla K. K., Kumar A., Gadupudi G. S., et al., *In Vitro* Characterization of a Multifunctional Staphylokinase Variant with Reduced Reocclusion, Produced from Salt Inducible *E. coli* GJ1158, BioMed Research International, 2013, Research Article: Hindawi Publishing Corporation.
23. Bokarewa M.I., Jin T. And Tarkowski A., *Staphylococcus aureus*: Staphylokinase, *Int J Biochem Cell Biol.* 2006; 38 (4):504-509.
24. Naseer SH. B., Ravi M., Gaddad S.M., Jayaraj Y.M. Screening of Staphylokinase producing *Staphylococcus aureus* from Clinical Samples, *International Journal of Research in Biological Sciences* 2014; 4 (2): 46-48.
25. Jasim H. M., Dellol R. A. And Hamzah A.S., Cloning of staphylokinase gene produced from mutant *S.aureus* in *E.coli*, *Inter. J. of Advanced Research*, 2015, 3 (10): 276- 285.
26. Cao R., Zeaki N., Wallin-Carlquist N., et al., Elevated Enterotoxin A Expression and Formation in *Staphylococcus aureus* and Its Association with Prophage Induction, *J. of Appl. and Environ. Microbio.*, 2012, 78 (14) : 4942- 4948.
27. Zeman M., Mašláňová I., A., Indráková et.al, *Staphylococcus sciuri* bacteriophages double-convert for staphylokinase and phospholipase, mediate interspecies plasmid transduction, and package *mecA* gene, *J. of Sci. Rep.*, 2017, 7, 46319; doi: 10.1038/srep46319.
28. Hua-Bo SU., Yu-Gao Z., Jin-Tian HE., Wei MO. et al., Construction and Characterization of Novel Staphylokinase Variants with Antiplatelet Aggregation Activity and Reduced Immunogenicity, *J. of Acta Biochimica et Biophysica Sinica*, 2004, 36 (5): 336-342.
29. Pulicherla K. K., Kumar A. and Gadupudi G. S. et al., *In Vitro* Characterization of a Multifunctional Staphylokinase Variant with Reduced Reocclusion, Produced from Salt Inducible *E. coli* GJ1158, *J. of BioMed Research Inter.* 2013; 12.
30. Łoś M., Kuzio J., McConnell M.I R., Kropinski A. M., et al., Applied and Industrial Microbiology: Lysogenic Conversion in Bacteria of Importance to the Food Industry, chapter 9, Lysogenic Conversion in Bacteria of Importance to the Food, *Bacteriophages in the Control of Food-and Waterborne Pathogens*. ASM Press, Washington, DC 2010, ; 157-198.
31. Elbashiti T.A., Production of Staphylokinase from Locally Isolated Lysogenic *Staphylococcus aureus*, *The Pharmaceutical and Chemical Journal*, 2017, 4, (1):25-31.

الكشف عن الجين (ساك) والتعبير عن أنزيم ستافيلوكاينيز في عزلات سريرية مختلفة لأنواع من

بكتيريا المكورات العنقودية

سهى ماهر عبد ، عدنان فاضل العزاوي

قسم علوم الحياة ، كلية العلوم ، جامعة تكريت ، تكريت ، العراق

الملخص

اجريت هذه الدراسة لأجل التحقق من وجود انزيم ستافيلوكاينيزالمحلل مظهرها ووراثيا حيث اشتملت على 100 عزلة لبكتيريا المكورات العنقودية تم جمع العينات من مصادر سريرية مختلفة. وقد اعتمدت الاختبارات المظهرية والكيميائية الحيوية تلاها للتأكيد استخدام تقنية Vitek2 لتشخيص أنواع المكورات المستحصلة. أجريت اختبارات الفحص المظهري التي تضمنت اختبارين هما فحص تحليل كازاين الحليب و فحص تحليل أجار بلازما الدم المسخن للتحقق من إنتاج انزيم ستافيلوكايناز من قبل المكورات العنقودية. ومن أصل 100 عزلة، أظهرت 32 عزلة نشاط (ساك) فقط، كان 29 منها يمثل النوع الذهبي *S. aureus* بينما 3 منها تنتمي إلى أنواع أخرى. تم إخضاع جميع العزلات إلى تفاعل سلسلة البلمرة المتعدد (PCR) لتحديد ما إذا كانت تمتلك الجين. وقد أثبت هذا البحث بالتأكد أنه ليس كل عزلات المكورات العنقودية الذهبية لديها الجين (ساك) (*sak*)، إلا أنه فقط البكتيريا المصابة بالعائى تمتلك الانزيم المنتقل إليها من خلاله وأنه ليس بالضرورة وجوده بهذا النوع فقط ولكن أيضا الأنواع المكورات العنقودية الأخرى يمكن أن تحتويه.